

Freedom of Information Request	FOI 22-214	24 th May 2022
--------------------------------	------------	---------------------------

I am researching the incidence and treatment of CLL and MCL. I would greatly appreciate if you could answer the following questions.

Q1. How many patients has your trust treated in the past 3 months for the following conditions:

- **Chronic Lymphocytic Leukaemia (CLL)**
- **Mantle Cell Lymphoma (MCL)**
- **In case you do not treat either of the above conditions, please tell us which trust or hospital you refer patients to.**

	Feb-22	Mar-22	Apr-22
CLL	<5	<5	<5
MCL	0	0	0

The Health Board has applied Section 40 of the Freedom of Information Act 2000. The Health Board will not provide the exact numbers due to the low numbers of individuals involved (5 or less). The Health Board believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:

- **BR (bendamustine + rituximab)**
- **Calquence (acalabrutinib)**
- **FCR (fludarabine + cyclophosphamide + rituximab)**
- **Gazyva (obinutuzumab) + chlorambucil**
- **Imbruvica (ibrutinib)**
- **Venclexta (venetoclax)**
- **Venclexta (venetoclax) + Gazyva (obinutuzumab)**
- **Venclexta (venetoclax) + rituximab**
- **Zydelig (idelalisib) + rituximab**
- **Any other systemic anti-cancer therapy**

Please find below the quantities dispensed in the Health Boards pharmacy for unknown diagnosis only for February, March and April 2022.

Please note the Health Board is only able to supply information by quantity and not by the number of patients treated:

Type	Qty
ACALABRUTINIB 100 mg Capsules 60 Capsule Pack	52
BENDAMUSTINE HYDROCHLORIDE 100 mg Intravenous Infusion 5 Vial Pack	4
BENDAMUSTINE HYDROCHLORIDE 25 mg Intravenous Infusion 5 Vial Pack	6
BORTEZOMIB (1.71mg - 2.6mg) IN SODIUM CHLORIDE 0.9% Pre-Filled Syringe 1 Syringe Pack	59
BORTEZOMIB 1.45 mg in 0.58mL Subcutaneous Injection 1 Syringe Pack	13
BORTEZOMIB 1.6 mg in 0.64mL Subcutaneous Injection 1 Syringe Pack	2
BORTEZOMIB 1.8 mg in 0.72mL Subcutaneous Injection 1 Syringe Pack	21
BORTEZOMIB 2 mg in 0.8mL Subcutaneous Injection 1 Syringe Pack	54
BORTEZOMIB 2.25 mg in 0.9mL Subcutaneous Injection 1 Syringe Pack	89
BORTEZOMIB 2.5 mg in 1mL Subcutaneous Injection 1 Syringe Pack	84
BORTEZOMIB 2.75 mg in 1.1mL Subcutaneous Injection 1 Syringe Pack	14
BORTEZOMIB 3 mg in 1.2mL Subcutaneous Injection 1 Syringe Pack	21
CHLORAMBUCIL 2 mg Tablets 25 Tablet Pack	3
CYCLOPHOSPHAMIDE (1251mg-1500mg) in SODIUM CHLOR 0.9%(500mL) Intravenous Infusion 1 Bag Pack	4
CYCLOPHOSPHAMIDE (2501mg - 2750mg) IN MULTILAYER PN BAG Intravenous Infusion 1 Bag Pack	4
CYCLOPHOSPHAMIDE (2751mg - 3000mg) IN MULTILAYER PN BAG Intravenous Infusion 1 Bag Pack	5
CYCLOPHOSPHAMIDE (501mg - 750mg) Syringe 1 Syringe Pack	1
CYCLOPHOSPHAMIDE (501mg-750mg) in SODIUM CHLOR 0.9%(500mL) Intravenous Infusion 1 Bag Pack	4
CYCLOPHOSPHAMIDE 150 mg in 7.5mL Intravenous Injection 1 Syringe Pack	24
CYCLOPHOSPHAMIDE 400 mg in 20mL Intravenous Injection 1 Syringe Pack	51
CYCLOPHOSPHAMIDE 50 mg Tablets 100 Tablet Pack	27
CYCLOPHOSPHAMIDE 500 mg in 25mL Intravenous Injection 1 Syringe Pack	84
CYCLOPHOSPHAMIDE 700 mg in 35mL Intravenous Injection 1 Syringe Pack	83
CYCLOPHOSPHAMIDE 800 mg in 40mL Intravenous Injection 1 Pre-Filled Syringe Pack	95
CYTARABINE (0mg - 50mg) Syringe 1 Syringe Pack	10
CYTARABINE (3001mg - 4000mg) in SODIUM CHLORIDE 0.9% (500mL) Intravenous Infusion 1 Bag Pack	10
CYTARABINE 100 mg in 5mL Injection 5 Vial Pack	14
DOXORUBICIN 25 mg in 12.5mL Intravenous Injection 1 Syringe Pack	7
DOXORUBICIN 30 mg in 15mL Intravenous Injection 1 Syringe Pack	36

Type	Qty
DOXORUBICIN 40 mg in 20mL Intravenous Injection 1 Syringe Pack	81
DOXORUBICIN 50 mg in 25mL Intravenous Injection 1 Syringe Pack	53
DOXORUBICIN 60 mg in 30mL Intravenous Injection 1 Syringe Pack	1
DOXORUBICIN HYDROCHLORIDE 50 mg in 25mL Injection 1 Vial Pack	20
IBRUTINIB 140 mg Tablets 28 Tablet Pack	19
IBRUTINIB 280 mg Tablets 28 Tablet Pack	18
IBRUTINIB 420 mg Tablets 28 Tablet Pack	111
IBRUTINIB 560 mg Tablets 28 Tablet Pack	13
IDELALISIB 100 mg Tablets 60 Tablet Pack	3
IDELALISIB 150 mg Tablets 60 Tablet Pack	1
OBINUTUZUMAB 1000 mg in 40mL Intravenous Infusion 1 Vial Pack	3
RITUXIMAB (MABTHERA) 1400 mg in 11.7mL Subcutaneous Injection 1 Vial Pack	59
RITUXIMAB (RIXATHON) 100 mg in 10mL Intravenous Infusion 2 Vial Pack	68
RITUXIMAB (RIXATHON) 500 mg in 50mL Intravenous Infusion 1 Vial Pack	137
VENETOCLAX 100 mg Tablets 112 Tablet Pack	3
VENETOCLAX 100 mg Tablets 14 Tablet Pack	5
VINCRIStINE 1mg in SODIUM CHLORIDE 0.9% (50mL) Intravenous Infusion 1 Bag Pack	67
VINCRIStINE 2mg in SODIUM CHLORIDE 0.9% (50mL) Intravenous Infusion 1 Bag Pack	47

Q3. How many Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months with the following:

- **BR (bendamustine + rituximab)**
- **Imbruvica (ibrutinib)**
- **Imbruvica (ibrutinib) + rituximab**
- **R-BAC (rituximab, bendamustine and cytarabine)**
- **R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone)**
- **Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone)**
- **Velcade (bortezomib) + chemotherapy**
- **Any other systemic anti-cancer therapy**
- **Stem cell transplant**
- **Tecartus (CAR-T) - Autologous anti-CD19-transduced CD3+ cells**

Please refer to Q2.

Q4. Does your trust currently participate in any ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL)? If so, can you please provide the name of each trial along with the number of patients taking part?

Flair - No patients currently on active treatment, but 8 patients in follow-up.

Q5. Does your trust currently participate in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

Beigene – opening the beginning of May 2022 - No patients.